Psychedelics

Latest News

positive results
BPL-003: Rapid, Durable Treatment for TRD Sees Positive Phase 2 Results

March 27th 2024

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.

psychedelics
Psychedelics and Psychiatry a Year Later

March 22nd 2024

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.
The Week in Review: March 11-15

March 16th 2024

blue psychedelic
Dune and The Third Coming of the Psychedelics

March 11th 2024

anxiety
FDA Grants Breakthrough Designation to MM-120 for Generalized Anxiety Disorder

March 7th 2024

Latest CME Events & Activities

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

More News

© 2024 MJH Life Sciences

All rights reserved.